Luc Puis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Luc Puis has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Aleksandar Nikolic
Department of Cardiac Surgery, Acibadem Sistina Hospital , Skopje, North Macedonia
2 shared publications- Christa Boer
Department of Anaesthesiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, the Netherlands
2 shared publications David Fitzgerald
Division of Cardiovascular Perfusion, The Medical University of South Carolina , Charleston, SC
2 shared publications- Diego Salmerón
Health and Social Sciences Department University of Murcia Murcia 30120 Spain
2 shared publications EACTS/EACTA/EBCP Committee Reviewers
2 shared publications- Filip De Somer
Heart Centre, University Hospital Ghent, Gent, Belgium
2 shared publications
Latest Publications
- Open Access
- 13 March 2026
- Published by EDP Sciences in The Journal of ExtraCorporeal Technology
- Vol. 58 (1) , 1-2
The never-ending process of adaptation
AmSECT’s Journal of ExtraCorporeal Technology is the premier global source of the most current research and information related to extracorporeal technology.
- 13 March 2026
- Published by EDP Sciences in The Journal of ExtraCorporeal Technology
- Vol. 58 (1) , 1-2
Open AccessThe never-ending process of adaptation
AmSECT’s Journal of ExtraCorporeal Technology is the premier global source of the most current research and information related to extracorporeal technology.
- Open Access
- 24 March 2023
- Published by EDP Sciences in The Journal of ExtraCorporeal Technology
- Vol. 55 (1) , 30-38
Haematic antegrade repriming to enhance recovery after cardiac surgery from the perfusionist side
Background: New era of cardiac surgery aims to provide an enhanced postoperative recovery through the implementation of every step of the process. Thus, perfusion strategy should adopt evidence-based measures to reduce the impact of cardiopulmonary bypass (CPB). Hematic Antegrade Repriming (HAR) provides a standardized procedure combining several measures to reduce haemodilutional priming to 300 mL. Once the safety of the procedure in terms of embolic release has been proven, the evaluation of its beneficial effects in terms of transfusion and ICU stay should be assessed to determine if could be considered for inclusion in Enhanced Recovery After Cardiac Surgery (ERACS) programs.Methods: Two retrospective and non-randomized cohorts of high-risk patients, with similar characteristics, were assessed with a propensity score matching model. The treatment group (HG) (n = 225) received the HAR. A historical cohort, exposed to conventional priming with 1350 mL of crystalloid confirmed the control group (CG) (n = 210).Results: Exposure to any transfusion was lower in treated (66.75% vs. 6.88%,p < 0.01). Prolonged mechanical ventilation (>10 h) (26.51% vs. 12.62%;p < 0.01) and extended ICU stay (>2 d) (47.47% vs. 31.19%;p < 0.01) were fewer for treated. HAR did not increase early morbidity and mortality. Related savings varied from 581 to 2741.94 $/patient, depending on if direct or global expenses were considered.Discussion: By reducing the gaseous and crystalloid emboli during CPB initiation, HAR seems to have a beneficial impact on recovery and reduces the overall transfusion until discharge, leading to significant cost savings per process. Due to the preliminary and retrospective nature of the research and its limitations, our findings should be validated by future prospective and randomized studies.
- 24 March 2023
- Published by EDP Sciences in The Journal of ExtraCorporeal Technology
- Vol. 55 (1) , 30-38
Open AccessHaematic antegrade repriming to enhance recovery after cardiac surgery from the perfusionist side
Background: New era of cardiac surgery aims to provide an enhanced postoperative recovery through the implementation of every step of the process. Thus, perfusion strategy should adopt evidence-based measures to reduce the impact of cardiopulmonary bypass (CPB). Hematic Antegrade Repriming (HAR) provides a standardized procedure combining several measures to reduce haemodilutional priming to 300 mL. Once the safety of the procedure in terms of embolic release has been proven, the evaluation of its beneficial effects in terms of transfusion and ICU stay should be assessed to determine if could be considered for inclusion in Enhanced Recovery After Cardiac Surgery (ERACS) programs.Methods: Two retrospective and non-randomized cohorts of high-risk patients, with similar characteristics, were assessed with a propensity score matching model. The treatment group (HG) (n = 225) received the HAR. A historical cohort, exposed to conventional priming with 1350 mL of crystalloid confirmed the control group (CG) (n = 210).Results: Exposure to any transfusion was lower in treated (66.75% vs. 6.88%,p < 0.01). Prolonged mechanical ventilation (>10 h) (26.51% vs. 12.62%;p < 0.01) and extended ICU stay (>2 d) (47.47% vs. 31.19%;p < 0.01) were fewer for treated. HAR did not increase early morbidity and mortality. Related savings varied from 581 to 2741.94 $/patient, depending on if direct or global expenses were considered.Discussion: By reducing the gaseous and crystalloid emboli during CPB initiation, HAR seems to have a beneficial impact on recovery and reduces the overall transfusion until discharge, leading to significant cost savings per process. Due to the preliminary and retrospective nature of the research and its limitations, our findings should be validated by future prospective and randomized studies.
- Open Access
- 23 May 2022
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (3) , 324-331
Hematic Antegrade Repriming Reduces Emboli on Cardiopulmonary Bypass: A Randomized Controlled Trial
Particulate and gaseous microemboli (GME) are side effects of cardiac surgery that interfere with postoperative recovery by causing endothelial dysfunction and vascular blockages. GME sources during surgery are multiple, and cardiopulmonary bypass (CPB) is contributory to this embolic load. Hematic antegrade repriming (HAR) is a novel procedure that combines the benefits of repriming techniques with additional measures, by following a standardized procedure to provide a reproducible hemodilution of 300 ml. To clarify the safety of HAR in terms of embolic load delivery, a prospective and controlled study was conducted, by applying Doppler probes to the extracorporeal circuit, to determine the number and volume of GME released during CPB. A sample of 115 patients (n = 115) was considered for assessment. Both groups were managed under strict normothermia, and similar clinical conditions and protocols, receiving the same open and minimized circuit. Significant differences in GME volume delivery (control group [CG] = 0.28 ml vs. HAR = 0.08 ml; p = 0.004) and high embolic volume exposure (>1 ml) were found between the groups (CG = 30.36% vs. HAR = 4.26%; p = 0.001). The application of HAR did not represent an additional embolic risk and provided a four-fold reduction in the embolic volume delivered to the patient (coefficient, 0.24; 95% CI, 0.08–0.72; p = 0.01), which appears to enhance GME clearance of the oxygenator before CPB initiation.
- 23 May 2022
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (3) , 324-331
Open AccessHematic Antegrade Repriming Reduces Emboli on Cardiopulmonary Bypass: A Randomized Controlled Trial
Particulate and gaseous microemboli (GME) are side effects of cardiac surgery that interfere with postoperative recovery by causing endothelial dysfunction and vascular blockages. GME sources during surgery are multiple, and cardiopulmonary bypass (CPB) is contributory to this embolic load. Hematic antegrade repriming (HAR) is a novel procedure that combines the benefits of repriming techniques with additional measures, by following a standardized procedure to provide a reproducible hemodilution of 300 ml. To clarify the safety of HAR in terms of embolic load delivery, a prospective and controlled study was conducted, by applying Doppler probes to the extracorporeal circuit, to determine the number and volume of GME released during CPB. A sample of 115 patients (n = 115) was considered for assessment. Both groups were managed under strict normothermia, and similar clinical conditions and protocols, receiving the same open and minimized circuit. Significant differences in GME volume delivery (control group [CG] = 0.28 ml vs. HAR = 0.08 ml; p = 0.004) and high embolic volume exposure (>1 ml) were found between the groups (CG = 30.36% vs. HAR = 4.26%; p = 0.001). The application of HAR did not represent an additional embolic risk and provided a four-fold reduction in the embolic volume delivered to the patient (coefficient, 0.24; 95% CI, 0.08–0.72; p = 0.01), which appears to enhance GME clearance of the oxygenator before CPB initiation.
- Open Access
- 2 October 2019
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 30 (2) , 161-202
2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery
TABLE OF CONTENTS
- 2 October 2019
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 30 (2) , 161-202
Open Access2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery
TABLE OF CONTENTS
- 2 October 2019
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 57 (2) , 210-251
2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery
- 2 October 2019
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 57 (2) , 210-251
2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery
- 1 January 2009
- Published by SAGE Publications in Perfusion
- Vol. 24 (1) , 51-52
Case report: plasma leakage in a polymethylpentene oxygenator during extracorporeal life support
Plasma leakage is a phenomenon which has almost completely disappeared since the introduction of plasma-tight polymethylpentene (PMP) fibers in oxygenators used for extracorporeal life support (ECLS). We describe here a case of ECLS which was affected by the rapid occurrence of plasma leakage in oxygenators with polymethylpentene fibers. To our knowledge, this is the first report of the phenomenon since the introduction of this new generation of oxygenators.
- 1 January 2009
- Published by SAGE Publications in Perfusion
- Vol. 24 (1) , 51-52
Case report: plasma leakage in a polymethylpentene oxygenator during extracorporeal life support
Plasma leakage is a phenomenon which has almost completely disappeared since the introduction of plasma-tight polymethylpentene (PMP) fibers in oxygenators used for extracorporeal life support (ECLS). We describe here a case of ECLS which was affected by the rapid occurrence of plasma leakage in oxygenators with polymethylpentene fibers. To our knowledge, this is the first report of the phenomenon since the introduction of this new generation of oxygenators.